论著 · 基础研究

CBX8抑制前列腺癌细胞侵袭的机制研究

  • 杨万里 ,
  • 宋娟 ,
  • 李兵 ,
  • 劳一敏
展开
  • 上海交通大学基础医学院生物化学与分子细胞生物学系,上海 200025
杨万里(1993—),男,硕士生;电子信箱:wanliyang1993@outlook.com
李 兵,电子信箱:bingli@shsmu.edu.cn
劳一敏,电子信箱:laoyimin@sjtu.edu.cn

收稿日期: 2023-08-30

  录用日期: 2023-11-07

  网络出版日期: 2024-02-01

基金资助

国家自然科学基金(81802773)

Deciphering the suppressive effects of CBX8 on prostate cancer cell invasion

  • Wanli YANG ,
  • Juan SONG ,
  • Bing LI ,
  • Yimin LAO
Expand
  • Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
LI Bing, E-mail: bingli@shsmu.edu.cn.
LAO Yimin, E-mail: laoyimin@sjtu.edu.cn

Received date: 2023-08-30

  Accepted date: 2023-11-07

  Online published: 2024-02-01

Supported by

National Natural Science Foundation of China(81802773)

摘要

目的·探究染色质组织调节框同源蛋白8(chromobox protein homolog 8,CBX8)在前列腺癌中的生物学功能,并通过转录组及表观修饰分析揭示CBX8在前列腺癌转移中的作用机制。方法·利用cBioPortal数据库对癌症基因组图谱(The Cancer Genome Atlas,TCGA)中前列腺腺癌(prostate adenocarcinoma,PRAD)患者样本数据集进行CBX家族蛋白mRNA表达分析。采用短发夹RNA技术敲低DU145前列腺癌细胞系中的CBX8,通过CCK-8和Transwell实验检测细胞增殖和侵袭水平的变化。使用RNA转录组测序(RNA-seq)分析敲低CBX8后影响的差异表达基因。对这些差异表达基因进行基因集富集分析(Gene Set Enrichment Analysis,GSEA)、基因本体论(Gene Ontology,GO)功能分析以及京都基因和基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)信号通路富集分析。通过染色质免疫沉淀测序(ChIP-seq)观察和测定敲低CBX8后基因组H3K27me3甲基化水平的变化。结果·根据对TCGA-PRAD患者样本数据的分析,发现CBX8 mRNA在前列腺癌中高表达。在前列腺癌细胞系DU145中敲低CBX8后,细胞的增殖能力没有显著变化(P>0.05),但其侵袭能力却显著提高(P<0.05)。RNA-seq分析显示CBX8敲低导致750个基因表达上调,951个基因表达下调;其中,与多种肿瘤转移有关的支链氨基酸转氨酶1(branched-chain-amino-acid aminotransferase 1,BCAT1)在敲除CBX8后表达明显上升。GSEA显示表达水平受影响的基因与多梳蛋白复合体1(polycomb repressive complex 1,PRC1)的功能有关。同时,通过GO和KEGG信号通路富集分析发现受影响的生物过程包括转运RNA(transfer RNA,tRNA)氨酰化、DNA复制、氨酰基-tRNA连接酶活性变化以及钙黏蛋白的结合等;特别是在GO功能分析的细胞组分方面富集了与肿瘤转移有关的细胞-基底连接相关基因。利用ChIP-seq对表观修饰的研究显示,在敲低CBX8后全基因组的H3K27me3水平有所下降;并鉴定了97个位于CBX8敲低后转录上调基因附近的位点,其中包括BCAT1转录起始位点。结论·CBX8在人前列腺癌中高表达。CBX8具有抑制肿瘤细胞侵袭的功能。其机制可能是CBX8/PRC1复合体结合于BCAT1转录起始位点并抑制BCAT1转录。

本文引用格式

杨万里 , 宋娟 , 李兵 , 劳一敏 . CBX8抑制前列腺癌细胞侵袭的机制研究[J]. 上海交通大学学报(医学版), 2023 , 43(12) : 1507 -1519 . DOI: 10.3969/j.issn.1674-8115.2023.12.005

Abstract

Objective ·To elucidate the regulatory mechanisms of the chromobox protein homolog 8 (CBX8) in prostate cancer metastasis from transcriptome and epigenetic modification perspectives. Methods ·The correlation between the expression of CBX proteins and prostate adenocarcinoma (PRAD) in The Cancer Genome Atlas (TCGA) was examined through an analysis based on cBioPortal database. A stable CBX8 knockdown DU145 prostate cancer cell line was established via short hairpin RNA (shRNA) transfection. Subsequently, the proliferation and invasion of the CBX8 knockdown cells were analyzed by CCK-8 assay and Transwell assay, respectively. Transcriptome changes of the CBX8 knockdown cells were investigated through RNA sequencing (RNA-seq) coupled with Gene Set Enrichment Analysis (GSEA). To further evaluate the functional implications of these transcriptomic alterations, Gene Ontology (GO) for functional analysis was deployed. Moreover, to identify potentially affected signalling pathways, the Kyoto Encyclopedia of Genes and Genomes (KEGG) was utilized for pathway enrichment analysis. Lastly, the levels of H3K27me3, a key histone modification associated with CBX8, in the knockdown cells were determined by chromatin immunoprecipitation sequencing (ChIP-seq). Results ·Bioinformatic analysis with cBioPortal database, based on TCGA-PRAD cohorts, unveiled a high CBX8 mRNA expression in PRAD. Knockdown of CBX8 did not significantly affect the proliferation of DU145 cells (P>0.05), but caused a a significant increase in their invasiveness (P<0.05). The RNA-seq analysis revealed that CBX8 knockdown led to the upregulation of 750 genes and the downregulation of 951 genes. Notably, branched-chain-amino-acid aminotransferase 1 (BCAT1), a gene implicated in the metastasis of various types of cancers, showed a significant increase in expression following CBX8 knockdown. GSEA showed that the expression levels were of the affected genes were related to the functions of the polycomb repressive complex 1 (PRC1). A further investigation using GO and KEGG analyses identified several enriched pathways in the CBX8 knockdown cells, including transfer RNA (tRNA) aminoacylation, DNA replication, changes in aminoacyl-tRNA ligase activity, and cadherin binding. Interestingly, in terms of cell component of GO functional analysis, cell-substrate junction-related genes associated with tumor metastasis appeared to be enriched. ChIP-seq results showed a global decrease in H3K27me3 levels. Significantly, 97 reduced H3K27me3 peaks were found located nearby genes that were upregulated upon CBX8 knockdown, including the transcriptional start site of BCAT1. Conclusion ·CBX8 is highly expressed in prostate cancer. CBX8 suppresses prostate cancer cell invasion, possibly by recruiting the transcriptional repressive PRC1 complex to the transcription site of BCAT1, thereby inhibiting BCAT1 transcription and tumor metastasis.

参考文献

1 ZHANG S W, SUN K X, ZHENG R S, et al. Cancer incidence and mortality in China, 2015[J]. J Natl Cancer Cent, 2021, 1(1): 2-11.
2 GERSTBERGER S, JIANG Q W, GANESH K. Metastasis[J]. Cell, 2023, 186(8): 1564-1579.
3 PIUNTI A, SHILATIFARD A. The roles of Polycomb repressive complexes in mammalian development and cancer[J]. Nat Rev Mol Cell Biol, 2021, 22(5): 326-345.
4 LAUGESEN A, H?JFELDT J W, HELIN K. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation[J]. Mol Cell, 2019, 74(1): 8-18.
5 SU W J, HAN H H, WANG Y, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression[J]. Cancer Cell, 2019, 36(2): 139-155.e10.
6 JUNG J, BUISMAN S C, WEERSING E, et al. CBX7 induces self-renewal of human normal and malignant hematopoietic stem and progenitor cells by canonical and non-canonical interactions[J]. Cell Rep, 2019, 26(7): 1906-1918.e8.
7 KLAUKE K, RADULOVI? V, BROEKHUIS M, et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation[J]. Nat Cell Biol, 2013, 15(4): 353-362.
8 DEL GAUDIO N, DI COSTANZO A, LIU N Q, et al. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway[J]. Mol Cancer, 2022, 21(1): 125.
9 HU F F, CHEN H, DUAN Y, et al. CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma[J]. Mol Ther Nucleic Acids, 2021, 27: 670-684.
10 WANG X, QIN G, LIANG X T, et al. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma[J]. Nat Commun, 2020, 11(1): 1141.
11 ZHANG C Z, CHEN S L, WANG C H, et al. CBX8 exhibits oncogenic activity via AKT/β-catenin activation in hepatocellular carcinoma[J]. Cancer Res, 2018, 78(1): 51-63.
12 MENG Q C, LI L, WANG L P. High CBX8 expression leads to poor prognosis in laryngeal squamous cell carcinoma by inducing EMT by activating the Wnt/β-catenin signaling pathway[J]. Front Oncol, 2022, 12: 881262.
13 DENG H L, GUAN X W, GONG L C, et al. CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer[J]. Sci Rep, 2019, 9(1): 197.
14 HUANG Z N, YAN Y L, ZHU Z, et al. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling[J]. Cell Death Dis, 2021, 12(6): 537.
15 BERNARD D, MARTINEZ-LEAL J F, RIZZO S, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus[J]. Oncogene, 2005, 24(36): 5543-5551.
16 FORZATI F, FEDERICO A, PALLANTE P, et al. CBX7 is a tumor suppressor in mice and humans[J]. J Clin Invest, 2012, 122(2): 612-623.
17 ZHANG Y, KANG M, ZHANG B, et al. m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5[J]. Mol Cancer, 2019, 18(1): 185.
18 WANG G, TANG J J, ZHAN W X, et al. CBX8 suppresses tumor metastasis via repressing snail in esophageal squamous cell carcinoma[J]. Theranostics, 2017, 7(14): 3478-3488.
19 CONNELLY K E, WEAVER T M, ALPSOY A, et al. Engagement of DNA and H3K27me3 by the CBX8 chromodomain drives chromatin association[J]. Nucleic Acids Res, 2019, 47(5): 2289-2305.
20 CERAMI E, GAO J J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
21 SUBRAMANIAN A, TAMAYO P, MOOTHA V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J]. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550.
22 LIBERZON A, BIRGER C, THORVALDSDóTTIR H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection[J]. Cell Syst, 2015, 1(6): 417-425.
23 MAO L, CHEN J, LU X, et al. Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis[J]. Theranostics, 2021, 11(19): 9705-9720.
24 XU M, LIU Q Q, JIA Y L, et al. BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma[J]. Oncol Lett, 2016, 12(4): 2648-2656.
25 TANG J J, WANG G, ZHANG M F, et al. Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer[J]. Oncotarget, 2014, 5(21): 10778-10790.
26 SHANG S, YANG Y W, CHEN F, et al. TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer[J]. Sci Transl Med, 2022, 14(626): eabf0992.
27 JIANG Q, LI J, WANG J Y, et al. Inhibition of CDKL3 downregulates STAT1 thus suppressing prostate cancer development[J]. Cell Death Dis, 2023, 14(3): 189.
28 HATZIIEREMIA S, MOHAMMED Z, MCCALL P, et al. Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence[J]. Mol Carcinog, 2016, 55(11): 1667-1677.
29 KACHROO P, LEE M H, ZHANG L, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer[J]. J Exp Clin Cancer Res, 2013, 32(1): 97.
30 LERCHENMüLLER C, HEI?ENBERG J, DAMILANO F, et al. S100A6 regulates endothelial cell cycle progression by attenuating antiproliferative signal transducers and activators of transcription 1 signaling[J]. Arterioscler Thromb Vasc Biol, 2016, 36(9): 1854-1867.
31 WANG T, HAN S L, DU G. S100A6 represses Calu-6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis[J]. Cell Biochem Funct, 2021, 39(6): 771-779.
32 MOUSSA H F, BSTEH D, YELAGANDULA R, et al. Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing[J]. Nat Commun, 2019, 10(1): 1931.
33 MACRAE T A, FOTHERGILL-ROBINSON J, RAMALHO-SANTOS M. Regulation, functions and transmission of bivalent chromatin during mammalian development[J]. Nat Rev Mol Cell Biol, 2023, 24(1): 6-26.
34 TERRANOVA C J, TANG M, MAITITUOHETI M, et al. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy[J]. Cell Rep, 2021, 36(3): 109410.
35 CHAN H L, BECKEDORFF F, ZHANG Y S, et al. Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms[J]. Nat Commun, 2018, 9(1): 3377.
36 CHUNG C Y, SUN Z, MULLOKANDOV G, et al. Cbx8 acts non-canonically with Wdr5 to promote mammary tumorigenesis[J]. Cell Rep, 2016, 16(2): 472-486.
文章导航

/